Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer.

The data presented herein are supplementary to our published primary article "A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer"[1]. The exploratory analysis evaluated the impact of prior pegylated liposomal doxorubicin (PLD) therapy in patients who participated in a randomized, open-label study comparing combination therapy of trabectedin and PLD vs PLD alone in third-line recurrent ovarian cancer (ROC). These exploratory analyses showed that prior treatment with PLD in ROC does not impact the response and survival rates nor does it increase toxicities or negatively influence survival and response rates in both treatment groups.

Informations de copyright

© 2020 The Author(s).

Déclaration de conflit d'intérêts

Bradley J. Monk reports personal fees from Abbvie, personal fees from Advaxis, personal fees from Agenus, personal fees from Amgen, personal fees from AstraZeneca, personal fees from ChemoCare, personal fees from ChemoID, personal fees from Clovis, personal fees from Conjupro, personal fees from Easai, personal fees from Geistlich, personal fees from Genmab, personal fees from ImmunoGen, personal fees from Immunomedics, personal fees from Incyte, personal fees from Janssen (Johnson/Johnson), personal fees from Mateon (formally Oxigene), personal fees from Merck, personal fees from Myriad, personal fees from Nucana, personal fees from Oncomed, personal fees from Oncoquest, personal fees from Oncosec, personal fees from Perthera, personal fees from Pfizer, personal fees from Precison Oncology, personal fees from Puma, personal fees from Roche/Genentech, personal fees from Samumed, personal fees from Takeda, personal fees from Tesaro, personal fees from VBL, outside the submitted work. Thomas J, Herzog reports personal fees from J & J, personal fees from Clovis, personal fees from AstraZeneca, personal fees from Tesaro, personal fees from Roche, personal fees from Caris, outside the submitted work. Robert L. Coleman reports grants from NIH, grants from Gateway Foundation, grants from VFounation, during the conduct of the study; grants and personal fees fromAstraZeneca, grants fromMerck, personal fees from Tesaro, personal fees from Medivation, grants and personal fees from Clovis, personal fees from Gamamab, grants and personal fees from Genmab, grants and personal fees from Roche/Genentech, grants and personal fees from Janssen, personal fees from Agenus, personal fees from Regeneron, personal fees from OncoQuest, outside the submitted work. George Wang, Spyros Triantos, Scott Maul, Roland Knoblauch, Tracy McGowan, and Waleed Shalaby are employees of Johnson & Johnson and hold stocks.